Rakovina Therapeutics Inc. RKV.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.32% | 33.39% | 168.63% | 239.86% | 247.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.64% | 50.85% | 117.66% | 154.40% | 161.40% |
| Operating Income | 9.64% | -50.85% | -117.66% | -154.40% | -161.40% |
| Income Before Tax | 5.71% | -52.46% | -111.96% | -146.19% | -150.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.71% | -52.46% | -111.96% | -146.19% | -150.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.71% | -52.46% | -111.96% | -146.19% | -150.13% |
| EBIT | 9.64% | -50.85% | -117.66% | -154.40% | -161.40% |
| EBITDA | 10.61% | -56.58% | -137.53% | -188.09% | -202.38% |
| EPS Basic | 46.04% | 17.96% | -3.54% | -26.18% | -38.68% |
| Normalized Basic EPS | 46.45% | 18.35% | -4.05% | -25.69% | -38.19% |
| EPS Diluted | 45.32% | 17.77% | -2.70% | -25.06% | -35.01% |
| Normalized Diluted EPS | 46.45% | 18.35% | -4.05% | -25.69% | -38.19% |
| Average Basic Shares Outstanding | 81.46% | 100.23% | 118.69% | 103.61% | 74.60% |
| Average Diluted Shares Outstanding | 81.46% | 100.23% | 118.69% | 103.61% | 74.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |